YamauchiP.S., RizkD., KormeiliT.Current systemic therapies for psoriasis. Where are we now? J Am Acad Dermatol.2003; 49: S66–S77.
8.
StebbinsW.G., LebwohlM.G.Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther.2004; 17: 432–440.
9.
U.S. Department of Health and Human Services. Different Types of Vaccines. Understanding Vaccines: What They Are, How They Work.2003; 19–33.
10.
LoutanL.Vaccination of the immunocompromised patient. Biologicals.1997; 35: 231–236.
11.
GottleibAB, CasaleT.B., FrankelE.CD4+ T-cell-directed antibody reponses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol.2003; 49: 816–825.
12.
FominI., CaspiD., LevyV.Vaccination against influenza in Rheumatoid Arthritis: the effect of disease modifying drugs, including TNF α blockers. Ann Rheum Dis. Published online 13 July 2005; doi: 10.1136/ard.2005.036434.
13.
MeaseP.J., RitchlinC.T., MartinR.W.Pneumococcal vaccine response in psoriatic arthritis patients during treatment with alefacept. J Rheumatol.2004; 31: 1356–1361.
14.
ElkayamO., CaspiD., ReitblattT.The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Sem Arthritis Rheum.2004; 33: 283–288.
15.
Adalimumab [package insert].North Chicago (IL): Abbott Laboratories; 2004.